NovaBay Genomics priced its reverse merger with Ainos at a post-close implied valuation of $1.4 billion (USD) in filings dated June 2026, on the basis that the combined entity holds an AI-assisted liquid biopsy platform with a clear pathway through NMPA's Center for Drug Evaluation under the Class III medical device track. The clinical ledger: the pivotal study supporting the cytology module ran 1,203 subjects across three sites in Fujian Province, primary endpoint was sensitivity for cervical intraepithelial neoplasia grade 2 or above (CIN2+) at 91.2%, specificity 78.4%, but the regulatory submission covers only the cytology assist function, not the multi-cancer early detection claim the merger deck leads with. The MCDE claim rests on a 214-subject proof-of-concept study, no Phase 3 equivalent filed.

The capital is pricing a pan-cancer screening platform. The trial data supports a single-indication cytology assist tool in a well-served indication. NMPA's Center for Drug Evaluation has accepted the cytology submission for review, with a statutory 60-working-day clock running from May 8, 2026, which puts the first decision window at approximately August 28. The multi-cancer arm has no submission date on record at CDE's public disclosure portal as of June 20, 2026. Family-office positions that entered at the merger announcement are holding a $1.4 billion valuation on an August cytology read and a MCDE pipeline that does not yet have a regulatory address.